GSK to Deliver Earnings Growth over Next Decade

Dow Jones06-25 22:37

1437 GMT - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.K. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 25, 2026 10:37 ET (14:37 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646809159?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646809159","market":"sh","top_or_hot":-1,"title":"GSK to Deliver Earnings Growth over Next Decade","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1437 GMT - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 10:37 ET (14:37 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK to Deliver Earnings Growth over Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK to Deliver Earnings Growth over Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-25 22:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1437 GMT - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 25, 2026 10:37 ET (14:37 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646809159","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646809159","pubTimestamp":1782398220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1437 GMT - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.K. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%.  Dow Jones NewswiresJune 25, 2026 10:37 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"葛兰素史克将在未来十年实现盈利增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5},"content_text":"1437 GMT - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.K. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2026 10:37 ET (14:37 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646809159","isCrawlerRequest":true}